Abstract 189P
Background
NF-κB-interacting LncRNA (NKILA) plays an inhibitory role in the NF-κB pathway, which is a key regulator of inflammatory cytokines. These mediators, freely floating in ascitic fluid (AF), reflecting the molecular genetic characteristics of tumor cells in ovarian cancer (OC), and associated with epigenetic switches of key pathways of carcinogenesis remain poorly understood. The aim of the work was to study the expression of LncRNA NKILA and marker cytokines of the NF-kB pathway in ascites of patients with OC.
Methods
The study included 22 patients with ascitic OC at stage III-IV according to FIGO. Isolation of circulating nucleic acid was performed from 2 ml of the cell-free fraction of ascites before treatment using SileksMagNaDirect magnetic particles (Sileks, Russia). lncRNA NKILA expression in AF was determined by qPCR (CFX-96, BioRad). Determination of cytokines VEGFA, IL-6, MCP-1 in AF was performed by ELISA. According to the effect of platinum-containing chemotherapy (CT), the patients were divided into groups: 1 - progression against the background of CT and early relapse; 2 - nonrelapsive. Statistical data processing was carried out using Statistica 13.0.
Results
The study included 22 patients with ascitic OC at stage III-IV according to FIGO. Isolation of circulating nucleic acid was performed from 2 ml of the cell-free fraction of ascites before treatment using SileksMagNaDirect magnetic particles (Sileks, Russia). lncRNA NKILA expression in AF was determined by qPCR (CFX-96, BioRad). Determination of cytokines VEGFA, IL-6, MCP-1 in AF was performed by ELISA. According to the effect of platinum-containing chemotherapy (CT), the patients were divided into groups: 1 - progression against the background of CT and early relapse; 2 – non-relapsive. Statistical data processing was carried out using Statistica 13.0.
Conclusions
Thus, the study of the lncRNA NKILA profile in tumor ascites in relation to inflammatory cytokines of the NF-kB signaling pathway requires further study in the context of understanding the signatures in the formation of chemoresistance in advanced OC.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
247TiP - Addition of induction, concurrent and maintenance durvalumab to induction and concurrent chemoradiation vs induction and concurrent chemoradiation for previously untreated locoregionally advanced nasopharyngeal carcinoma: A phase II randomised-controlled trial
Presenter: Victor Lee
Session: Poster viewing 03
248P - The use of complementary medicine in Chinese pediatric patients receiving palliative care: A multi-centre study
Presenter: Chun SIng Lam
Session: Poster viewing 03
249P - Improving quality of life and symptom burden with opioids and adjuncts in lung cancer (IQSOL study)
Presenter: Naren Gokulanathan
Session: Poster viewing 03
250P - An analysis of nutritional and psychological status of patients with advanced cancer
Presenter: Shasha Wang
Session: Poster viewing 03
251P - Is QUAD SHOT palliative cyclical hypo-fractionated radiotherapy in advanced head and neck cancer the way to go? An alternative regimen in low resource countries
Presenter: Ravi Kanodia
Session: Poster viewing 03
252P - Preferred place of death among terminally ill cancer patients: A single centre observational study from India
Presenter: Suhana Sulfiker
Session: Poster viewing 03
253P - Hemostatic radiotherapy for gastric cancer: MRI as an alternative to endoscopy for post-treatment evaluation
Presenter: Osamu Tanaka
Session: Poster viewing 03
254P - Sexual function of cervical cancer survivors: A single center prospective study
Presenter: Dinesh Ravikumar
Session: Poster viewing 03
255P - Volunteers’ role to provide quality palliative care for terminal cancer
Presenter: SAPTAPARNA JANA
Session: Poster viewing 03